Evidence map›Paper›PMID 20686663›Full record

ArticlePLoS pathogens2010

The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement.

Lisa A Lewis, Jutamas Ngampasutadol, Ruth Wallace, Jane E A Reid, Ulrich Vogel, Sanjay Ram

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 158 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Mechanisms by which Factor H protectsFrontiers in immunology · 2024
    Article
  5. Pan-genome wide association study ofFrontiers in microbiology · 2023
    Article
  6. PathogenicInfection and immunity · 2022
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. The Host-Pathogen Interactions and Epicellular Lifestyle ofFrontiers in cellular and infection microbiology · 2022
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Interactions Between PathogenicFrontiers in cellular and infection microbiology · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Lisa A LewisDivision of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. lisa.lewis@umassmed.edu
Jutamas Ngampasutadol
Ruth Wallace
Jane E A Reid
Ulrich Vogel
Sanjay Ram
University of Massachusetts Chan Medical School · USTrinity College Dublin · IEUniversity of Würzburg · DE

Funding

Immunology of Infection with Neisseria gonorrhoeaeR37AI032725 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RICE, PETER A. · 2004 to 2013
$6.1M
Complement Activation on Neisseria meningitidisR01AI054544 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY · 2004 to 2014
$3.4M
IMMUNOLOGY OF INFECTION WITH NEISSERIA GONORRHOEAER01AI032725 · NIAID · BOSTON MEDICAL CENTER · PI RICE, PETER A. · 1993 to 2003
$1.8M
Immunology of Infection with Neisseria gonorrhoeaeR56AI032725 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAM, SANJAY, RICE, PETER A. · 2014 to 2014
$583k
NIAID NIH HHS AI054544NIAID NIH HHS AI32725NIAID NIH HHS R01 AI032725NIAID NIH HHS R01 AI054544NIAID NIH HHS R37 AI032725NIAID NIH HHS R56 AI032725
6 · The paper itself

Abstract

Complement forms an important arm of innate immunity against invasive meningococcal infections. Binding of the alternative complement pathway inhibitor factor H (fH) to fH-binding protein (fHbp) is one mechanism meningococci employ to limit complement activation on the bacterial surface. fHbp is a leading vaccine candidate against group B Neisseria meningitidis. Novel mechanisms that meningococci employ to bind fH could undermine the efficacy of fHbp-based vaccines. We observed that fHbp deletion mutants of some meningococcal strains showed residual fH binding suggesting the presence of a second receptor for fH. Ligand overlay immunoblotting using membrane fractions from one such strain showed that fH bound to a approximately 17 kD protein, identified by MALDI-TOF analysis as Neisserial surface protein A (NspA), a meningococcal vaccine candidate whose function has not been defined. Deleting nspA, in the background of fHbp deletion mutants, abrogated fH binding and mAbs against NspA blocked fH binding, confirming NspA as a fH binding molecule on intact bacteria. NspA expression levels vary among strains and expression correlated with the level of fH binding; over-expressing NspA enhanced fH binding to bacteria. Progressive truncation of the heptose (Hep) I chain of lipooligosaccharide (LOS), or sialylation of lacto-N-neotetraose LOS both increased fH binding to NspA-expressing meningococci, while expression of capsule reduced fH binding to the strains tested. Similar to fHbp, binding of NspA to fH was human-specific and occurred through fH domains 6-7. Consistent with its ability to bind fH, deleting NspA increased C3 deposition and resulted in increased complement-dependent killing. Collectively, these data identify a key complement evasion mechanism with important implications for ongoing efforts to develop meningococcal vaccines that employ fHbp as one of its components.

Indexed as

Antigens, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsComplement Factor HComplement System ProteinsHumansMeningococcal VaccinesProtein BindingAntigens, BacterialBacterial Outer Membrane ProteinsBacterial ProteinsComplement Factor HComplement System Proteinsfactor H-binding protein, Neisseria meningitidisMeningococcal VaccinesNspA protein, Neisseria

Identifiers

PMID20686663
PMCPMC2912398
OpenAlexW2018831327

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.